John Perfect

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant
    Barbara D Alexander
    Division of Infectious Diseases and International Health, Box 3035, Duke University Medical Center, Durham, NC 27710, USA
    Transplantation 86:791-6. 2008
  2. pmc Pleiotropic effects of deubiquitinating enzyme Ubp5 on growth and pathogenesis of Cryptococcus neoformans
    Wei Fang
    Shanghai Key Laboratory of Molecular Medical Mycology, PLA Key Laboratory of Mycosis, Institute of Dermatology and Mycosis of Changzheng Hospital, Second Military Medical University, Shanghai, China
    PLoS ONE 7:e38326. 2012
  3. doi request reprint Fungal diagnosis: how do we do it and can we do better?
    John R Perfect
    Duke University Medical Center, Durham, NC, USA
    Curr Med Res Opin 29:3-11. 2013
  4. doi request reprint The impact of the host on fungal infections
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Med 125:S39-51. 2012
  5. ncbi request reprint Cryptococcus neoformans: a sugar-coated killer with designer genes
    John R Perfect
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    FEMS Immunol Med Microbiol 45:395-404. 2005
  6. ncbi request reprint The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis
    J R Perfect
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Infect Dis 33:1824-33. 2001
  7. doi request reprint Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 50:291-322. 2010
  8. pmc Management of cryptococcosis: how are we doing?
    John R Perfect
    Division of Infectious Disease, Duke University Medical Center, Durham, NC, United States
    PLoS Med 4:e47. 2007
  9. ncbi request reprint Voriconazole treatment for less-common, emerging, or refractory fungal infections
    John R Perfect
    Department of Medicine and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 36:1122-31. 2003
  10. ncbi request reprint Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex
    John R Perfect
    Department of Medicine and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 40:S401-8. 2005

Detail Information

Publications86

  1. doi request reprint Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant
    Barbara D Alexander
    Division of Infectious Diseases and International Health, Box 3035, Duke University Medical Center, Durham, NC 27710, USA
    Transplantation 86:791-6. 2008
    ..In this post hoc analysis of a large, open-label, multicenter study, we evaluated efficacy and safety of posaconazole, a new extended-spectrum triazole, as salvage therapy for IFIs in SOT recipients...
  2. pmc Pleiotropic effects of deubiquitinating enzyme Ubp5 on growth and pathogenesis of Cryptococcus neoformans
    Wei Fang
    Shanghai Key Laboratory of Molecular Medical Mycology, PLA Key Laboratory of Mycosis, Institute of Dermatology and Mycosis of Changzheng Hospital, Second Military Medical University, Shanghai, China
    PLoS ONE 7:e38326. 2012
    ..neoformans. Therefore, deubiquitinating enzymes (especially Ubp5) are essential for the virulence composite of C. neoformans and provide an additional yeast survival and propagation advantage in the host...
  3. doi request reprint Fungal diagnosis: how do we do it and can we do better?
    John R Perfect
    Duke University Medical Center, Durham, NC, USA
    Curr Med Res Opin 29:3-11. 2013
    ..Many studies indicate that delayed or inaccurate diagnosis and treatment are major causes of poor outcomes in patients with IFIs...
  4. doi request reprint The impact of the host on fungal infections
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Med 125:S39-51. 2012
    ....
  5. ncbi request reprint Cryptococcus neoformans: a sugar-coated killer with designer genes
    John R Perfect
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    FEMS Immunol Med Microbiol 45:395-404. 2005
    ..C. neoformans has now become a primary model to study molecular fungal pathogenesis with the goal of identifying drug targets or vaccine strategies...
  6. ncbi request reprint The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis
    J R Perfect
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Infect Dis 33:1824-33. 2001
    ..Chronic necrotizing aspergillosis, aspergilloma, and allergic bronchopulmonary aspergillosis have variable management strategies and better short-term outcomes...
  7. doi request reprint Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 50:291-322. 2010
    ..However, if the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, then cryptococcosis can be managed successfully in the vast majority of patients...
  8. pmc Management of cryptococcosis: how are we doing?
    John R Perfect
    Division of Infectious Disease, Duke University Medical Center, Durham, NC, United States
    PLoS Med 4:e47. 2007
  9. ncbi request reprint Voriconazole treatment for less-common, emerging, or refractory fungal infections
    John R Perfect
    Department of Medicine and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 36:1122-31. 2003
    ..Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections...
  10. ncbi request reprint Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex
    John R Perfect
    Department of Medicine and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 40:S401-8. 2005
    ..In an area with little guidance for therapy, the CLEAR data indicate that ABLC can be an effective broad-spectrum treatment choice for several invasive and refractory non-Aspergillus mould infections...
  11. ncbi request reprint Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients
    John R Perfect
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Infect Dis 39:S207-10. 2004
    ..Despite widespread use of amphotericin B aerosols, there are still few studies on how to validate their effectiveness or optimize pharmacokinetics...
  12. ncbi request reprint Nuances of new anti-Aspergillus antifungals
    J R Perfect
    Duke University Medical Center, Durham, NC 27710, USA
    Med Mycol 43:S271-6. 2005
    ..However, significant progress has been made, and with careful use of the clinical tools available it is possible to make a successful impact on infection outcomes...
  13. ncbi request reprint Cryptococcosis
    John R Perfect
    Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, PO Box 3353, Durham, NC 27710, USA
    Infect Dis Clin North Am 16:837-74, v-vi. 2002
    ..This article collates and analyzes both new and old knowledge about the pathogen to help frame the meaning of human cryptococcosis as it starts to evolve in the new millennium...
  14. ncbi request reprint New antifungal agents
    J R Perfect
    Duke University Medical Center, Durham, NC, USA
    Transpl Infect Dis 4:52-61. 2002
  15. ncbi request reprint Cryptococcus neoformans: the yeast that likes it hot
    John R Perfect
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center Durham, NC 27710, USA
    FEMS Yeast Res 6:463-8. 2006
    ....
  16. ncbi request reprint Cryptococcus neoformans: virulence and host defences
    J R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    Med Mycol 36:79-86. 1998
    ..neoformans, the future of research in this area will require a certain critical mass of investigators to help share in the developmental costs which continue to occur...
  17. ncbi request reprint Management of invasive mycoses in hematology patients: current approaches
    John R Perfect
    Division of Infectious Disease, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncology (Williston Park) 18:5-14. 2004
    ..If patients are intolerant of or refractory to conventional therapy, effective alternatives include a lipid formulation of amphotericin B or an echinocandin...
  18. ncbi request reprint Use of newer antifungal therapies in clinical practice: what do the data tell us?
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncology (Williston Park) 18:15-23. 2004
    ..Caspofungin is effective against both invasive aspergillosis and invasive candidiasis...
  19. pmc Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target
    Methee Chayakulkeeree
    Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    Antimicrob Agents Chemother 51:3537-45. 2007
    ..neoformans with a potential for synergistic behavior with azoles...
  20. ncbi request reprint Antifungal resistance: the clinical front
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA
    Oncology (Williston Park) 18:15-22. 2004
    ..Caspofungin and voriconazole show good activity against most Candida species and may be good alternatives for patients with Candida glabrata and Candida krusei infections and for those with relapsing infections...
  21. pmc Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model
    Chiatogu Onyewu
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
    Antimicrob Agents Chemother 51:3743-6. 2007
    ..The fluconazole-FK506 combination demonstrated the most obvious advantage over single-drug therapy by clearing conidia and protecting skin from damage at low drug concentrations...
  22. pmc Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans
    Elizabeth Wills Petzold
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Infect Immun 74:5877-87. 2006
    ..These studies in C. neoformans and previous studies in other pathogenic fungi support the view of the trehalose pathway as a selective fungicidal target for use in antifungal development...
  23. ncbi request reprint Successful use of amphotericin B lipid complex in the treatment of cryptococcosis
    Larry M Baddour
    Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Infect Dis 40:S409-13. 2005
    ..A mean serum creatinine level decrease of 0.02 mg/dL occurred. ABLC was an effective treatment for cryptococcal infection in immunocompromised patients...
  24. pmc Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans
    Thomas H Rude
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Infect Immun 70:5684-94. 2002
    ..neoformans infection. Compounds that specifically target only ICL1 are unlikely to cripple C. neoformans growth in vivo...
  25. ncbi request reprint Outcome of lung transplantation in patients with mycetomas
    Denis Hadjiliadis
    Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Chest 121:128-34. 2002
    ..Pulmonary mycetomas are found in patients with end-stage lung diseases, especially sarcoidosis. The clinical course and long-term outcome of these patients after transplantation remains unknown...
  26. doi request reprint Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options
    Elizabeth Dodds Ashley
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durnham, North Carolina, USA
    Pharmacotherapy 32:890-901. 2012
    ..To determine the true institutional cost of treating invasive fungal infections in light of recent advances in diagnostic techniques and antifungal therapies for both treatment and prophylaxis of these infections...
  27. ncbi request reprint Cytochrome c peroxidase contributes to the antioxidant defense of Cryptococcus neoformans
    Steven S Giles
    Departments of Medicine and Molecular Genetics and Microbiology, Duke University Medical Center, P O Box 3353, Durham, NC 27710, USA
    Fungal Genet Biol 42:20-9. 2005
    ..neoformans...
  28. ncbi request reprint Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy
    Jane V Trinh
    Department of Pediatrics, Duke University, Durham, North Carolina 27710, USA
    Med Mycol 41:339-45. 2003
    ..Despite the fatal outcome for our patient, we encourage other clinicians to try unique medical approaches for this historically life-threatening infection when adjunctive surgery is impossible...
  29. pmc Role of alternative oxidase gene in pathogenesis of Cryptococcus neoformans
    Shamima Akhter
    Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    Infect Immun 71:5794-802. 2003
    ....
  30. pmc Calcineurin is essential for survival during membrane stress in Candida albicans
    M Cristina Cruz
    Department of Genetics, Duke University Medical Center, Durham, NC 27710, USA
    EMBO J 21:546-59. 2002
    ..albicans mutants, against other Candida species, or when combined with different azoles. We propose that calcineurin is part of a membrane stress survival pathway that could be targeted for therapy...
  31. pmc Mating-type-specific and nonspecific PAK kinases play shared and divergent roles in Cryptococcus neoformans
    Ping Wang
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Eukaryot Cell 1:257-72. 2002
    ....
  32. pmc Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus
    Jarrod R Fortwendel
    Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Antimicrob Agents Chemother 53:476-82. 2009
    ..Additionally, the calcineurin pathway elements cnaA and crzA play a major role in proper chitin and glucan incorporation into the A. fumigatus cell wall...
  33. ncbi request reprint Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs
    Jill R Blankenship
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Research Drive, Durham, NC 27710, USA
    Curr Opin Investig Drugs 4:192-9. 2003
    ..In summary, these highly successful pharmaceutical agents may find an even broader clinical application in combating infectious diseases...
  34. pmc The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii
    Popchai Ngamskulrungroj
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Infect Immun 77:4584-96. 2009
    ..gattii in the invertebrate and mammalian hosts. These results highlight the central importance of this pathway in the virulence composites of both pathogenic cryptococcal species...
  35. pmc The Cryptococcus neoformans catalase gene family and its role in antioxidant defense
    Steven S Giles
    Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA
    Eukaryot Cell 5:1447-59. 2006
    ..neoformans possesses a robust antioxidant system, composed of functionally overlapping and compensatory components that provide protection against endogenous and exogenous oxidative stresses...
  36. pmc Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin
    Jarrod R Fortwendel
    Departments of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Antimicrob Agents Chemother 54:1555-63. 2010
    ..Taken together, our data suggest a mechanistic role for A. fumigatus calcineurin signaling in the chitin biosynthetic response observed during paradoxical growth in the presence of high-dose caspofungin treatment...
  37. pmc Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis
    Anthony Lee
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
    Infect Immun 78:4213-25. 2010
    ..Our findings indicate that the genes required for C. neoformans survival in CSF ex vivo are necessary for survival and infection in this unique host environment...
  38. pmc Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus
    Robert A Cramer
    Duke University Medical Center, Box 3499, Pediatric Infectious Diseases, Durham, NC 27710, USA
    Eukaryot Cell 7:1085-97. 2008
    ..In addition, the importance of CrzA to the production of disease is critical, and thus CrzA is an attractive fungus-specific antifungal target for the treatment of invasive aspergillosis...
  39. pmc Identification of Cryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray
    Peter R Kraus
    Department of Molecular Genetics and Microbiology, 322 CARL Building, Box 3546, Research Dr, Duke University Medical Center, Durham, NC 27710, USA
    Eukaryot Cell 3:1249-60. 2004
    ..Our findings demonstrate the utility of even partial-genome microarrays for delineating regulatory cascades that contribute to microbial pathogenesis...
  40. pmc Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates
    Kirsten Nielsen
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Infect Immun 71:4831-41. 2003
    ..Our studies highlight a role for sexual recombination in the evolution of a human fungal pathogen and provide a robust genetic platform to establish the molecular determinants of virulence...
  41. ncbi request reprint Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts
    Brahm H Segal
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Infect Dis 44:402-9. 2007
    ..Finally, we discuss the implications of newer antifungal agents and diagnostic adjuncts in the design of future clinical trials to evaluate prophylaxis and early prevention strategies...
  42. ncbi request reprint Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak
    James A Fraser
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nature 437:1360-4. 2005
    ..This has implications for the emergence of other microbial pathogens and inbreeding in host range expansion in the fungal and other kingdoms...
  43. ncbi request reprint Evaluation and management of fungal infections in immunocompromised patients
    Priya Venkatesan
    Duke University School of Medicine, Durham, NC 27710, USA
    Dermatol Ther 18:44-57. 2005
    ..Recent advances in antifungal therapy and their direct application to specific diseases provide important new approaches to this complex and often seriously ill patient population...
  44. pmc Aspergillus fumigatus calcipressin CbpA is involved in hyphal growth and calcium homeostasis
    Nadthanan Pinchai
    Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Eukaryot Cell 8:511-9. 2009
    ..fumigatus and provides evidence that CbpA may serve as a feedback inhibitor in some aspects of calcineurin functions...
  45. pmc Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection
    Kirsten Nielsen
    Department of Molecular Genetics and Microbiology, 322 CARL Building, Research Drive, Duke University Medical Center, Durham, NC 27710, USA
    Infect Immun 73:4922-33. 2005
    ..These studies reveal the first virulence difference between congenic a and alpha strains in the most common pathogenic variety and suggest an explanation for the prevalence of alpha strains in clinical isolates...
  46. pmc The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans
    Chiatogu Onyewu
    Department of Molecular Genetics and Microbiology, 322 CARL Building, Box 3546, Research Drive, Duke University Medical Center, Durham, NC 27710, USA
    Infect Immun 72:7330-3. 2004
    ..Crz1 is a proposed downstream target of calcineurin based on studies of Saccharomyces cerevisiae. However, the in vitro phenotypes of C. albicans crz1/crz1 and calcineurin mutants differ and Crz1 is not required for virulence...
  47. doi request reprint Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update
    Dustin T Wilson
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, PO Box 3353, Durham, NC 27710, USA
    Mycopathologia 168:313-27. 2009
    ..Finally, therapeutic drug monitoring of select antifungals (notably posaconazole and voriconazole) may play an increasing role due to significant interpatient variability in serum concentrations after standard doses...
  48. pmc Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus
    William J Steinbach
    Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    Antimicrob Agents Chemother 51:2979-81. 2007
    ..Quantification of 1,3-beta-d-glucan revealed decreased amounts in the calcineurin A (DeltacnaA) mutant. Calcineurin can be an excellent adjunct therapeutic target in combination with other cell wall inhibitors against A. fumigatus...
  49. doi request reprint Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis
    Susanna Naggie
    Division of Infectious Diseases, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Chest Med 30:337-53, vii-viii. 2009
    ....
  50. pmc Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents
    Barbara D Alexander
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Microbiol 45:698-706. 2007
    ..However, further evaluation of their performance for determining the MICs of azoles, particularly for C. glabrata, is warranted...
  51. pmc Surfactant protein D increases phagocytosis of hypocapsular Cryptococcus neoformans by murine macrophages and enhances fungal survival
    Scarlett Geunes-Boyer
    Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Infect Immun 77:2783-94. 2009
    ..These findings provide evidence that C. neoformans subverts host defense mechanisms involving surfactant, establishing a novel virulence paradigm that may be targeted for therapy...
  52. ncbi request reprint Caspofungin for invasive candidiasis at a tertiary care medical center
    Aimee K Zaas
    Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 119:993.e1-6. 2006
    ..We report a single-center experience with 104 consecutive courses of caspofungin for the treatment of invasive candidiasis to evaluate a real-world performance of this drug...
  53. ncbi request reprint Candida glabrata endophthalmitis following penetrating keratoplasty
    Matthew C Caldwell
    Duke University Eye Center, Duke University Medical Center, Durham, North Carolina 27701, USA
    J Cataract Refract Surg 35:598-602. 2009
    ..In half the cases, there was a latent period of several months. These infections can be difficult to treat because C glabrata is often resistant to the antifungal agents commonly used to treat Candida albicans...
  54. ncbi request reprint Phylogenomic analysis of non-ribosomal peptide synthetases in the genus Aspergillus
    Robert A Cramer
    Duke University Medical Center, Department of Molecular Genetics and Microbiology, Durham, NC 27710, USA
    Gene 383:24-32. 2006
    ..Further analysis of these genes and their peptide products may identify important roles for secondary metabolites produced by NRPS in Aspergillus physiology, ecology, and fungal pathogenicity...
  55. ncbi request reprint Caspofungin: first approved agent in a new class of antifungals
    Melissa D Johnson
    Division of Infectious Diseases and International Health, Duke University Medical Center, Box 3306 DUMC, Durham, NC 27710, USA
    Expert Opin Pharmacother 4:807-23. 2003
    ..However, more clinical data are needed to define its role as primary therapy for invasive aspergillosis, and its role in combination antifungal therapy...
  56. pmc Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages
    Gary M Cox
    Department of Medicine and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA
    Infect Immun 71:173-80. 2003
    ..neoformans can compensate for the loss of the Cu,Zn SOD in vivo...
  57. ncbi request reprint Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases
    William J Steinbach
    Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Clin Infect Dis 39:192-8. 2004
    ..29; 95% CI, 0.15-0.56). Voriconazole is likely to be a better treatment choice for A. terreus infection than is a polyene...
  58. ncbi request reprint Antifungal pharmacotherapy for invasive mould infections
    Jason C Gallagher
    Duke University Medical Center, Division of Infectious Diseases, Box 3353, Durham, NC 27710, USA
    Expert Opin Pharmacother 4:147-64. 2003
    ..The administration of an optimal fungicidal therapy early in the course of the illness and control of the underlying disease are vital to prevent complications and mortality from these tenacious mycoses...
  59. ncbi request reprint A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution
    Melissa D Johnson
    Division of Infectious Diseases and International Health, Duke University Medical Center, Box 3306 DUMC, Durham, NC 27710, USA
    J Antimicrob Chemother 51:453-7. 2003
    ..Omeprazole did not significantly affect the C(max), T(max) or AUC(0-8) of itraconazole or hydroxyitraconazole when administered as IOS...
  60. ncbi request reprint Novel modes of antifungal drug administration
    Rebekah R Arthur
    Campbell University School of Pharmacy, Buies Creek, NC, USA
    Expert Opin Investig Drugs 13:903-32. 2004
    ..In contrast, the inhalation of antifungal aerosols, such as amphotericin B, is rapidly becoming a viable prophylactic option...
  61. pmc In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus
    William J Steinbach
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Antimicrob Agents Chemother 48:1664-9. 2004
    ..Our findings suggest a potential role for combination therapy with calcineurin pathway inhibitors and existing antifungal agents to augment activity against A. fumigatus...
  62. pmc Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide
    William J Steinbach
    Department of Pediatrics, Duke University, Durham, North Carolina 27710, USA
    J Clin Microbiol 41:3981-5. 2003
    ..We also review the treatments and outcomes of 28 reported cases of osteomyelitis or septic arthritis caused by Scedosporium species in immunocompetent patients...
  63. pmc In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection
    William J Steinbach
    Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Antimicrob Agents Chemother 48:3217-25. 2004
  64. ncbi request reprint Value of an inhalational model of invasive aspergillosis
    William J Steinbach
    Division of Pediatric Infectious Diseases, Box 3499, Duke University Medical Center, Durham, NC 27710, USA
    Med Mycol 42:417-25. 2004
    ....
  65. ncbi request reprint Is it time to abandon the use of amphotericin B bladder irrigation?
    Richard H Drew
    Campbell University School of Pharmacy, Buies Creek, North Carolina, USA
    Clin Infect Dis 40:1465-70. 2005
    ..The patient may be best served by removal of the urinary catheter, if possible, rather than by instillation of bladder irrigation with amphotericin B...
  66. ncbi request reprint Liposomal amphotericin B: clinical experience and perspectives
    Winter J Gibbs
    Department of Pharmacy Practice, Campbell University School of Pharmacy, Buies Creek
    Expert Rev Anti Infect Ther 3:167-81. 2005
    ..This review will focus primarily on recent liposomal amphotericin B experience and attempt to put its use into perspective considering other available antifungal agents...
  67. ncbi request reprint A meta-analysis of medical versus surgical therapy for Candida endocarditis
    William J Steinbach
    Division of Infectious Diseases, Department of Pediatrics, Duke University, Durham, NC 27710, USA
    J Infect 51:230-47. 2005
    ..The optimal management of Candida infective endocarditis (IE) is unknown...
  68. pmc Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus
    William J Steinbach
    Department of Pediatrics, Division of Pediatric Infectious Diseases, Box 3499, Duke University Medical Center, Durham, North Carolina 27710, USA
    Eukaryot Cell 5:1091-103. 2006
    ..Our findings reveal that calcineurin appears to play a globally conserved role in the virulence of several pathogenic fungi and yet plays specialized roles in each and can be an excellent target for therapeutic intervention...
  69. ncbi request reprint Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia
    Melanie W Pound
    Internal Medicine Infectious Diseases Academia, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Infect Dis 15:183-94. 2002
    ..Other echinocandin and triazole antifungals are under development in attempts to provide improved effective therapy for fungal pneumonia...
  70. pmc Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production
    Robert A Cramer
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
    Eukaryot Cell 5:972-80. 2006
    ..This result suggests that gliotoxin is not required for virulence in an immunosuppressed host with an invasive pulmonary infection...
  71. ncbi request reprint New antifungal agents
    Irene Lu
    Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC 27710, USA
    Semin Respir Infect 17:140-50. 2002
    ..Clinical antifungal drug resistance must be controlled by improving a series of antifungal therapeutic strategies...
  72. ncbi request reprint Candida endocarditis: contemporary cases from the International Collaboration of Infectious Endocarditis Merged Database (ICE-mD)
    Daniel K Benjamin
    Department of Pediatrics, Duke University, Durham, NC, USA
    Scand J Infect Dis 36:453-5. 2004
    ..We evaluated 16 patients with Candida IE nested within a cohort of 2,022 patients with IE. Prosthetic valve IE was more common in patients with Candida (50% vs 17%); mortality was 37% for patients with Candida...
  73. pmc Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production
    Mairi C Noverr
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ann Arbor, Michigan 48109 0642, USA
    Infect Immun 71:1538-47. 2003
    ..These data suggest that cryptococcal PLB1 may act as a virulence factor by enhancing the ability to survive macrophage antifungal defenses, possibly by facilitating fungal eicosanoid production...
  74. ncbi request reprint Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Pediatr Infect Dis J 21:240-8. 2002
    ..To describe the safety and efficacy of voriconazole in children treated within the compassionate release program...
  75. pmc Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis
    Eleftherios Mylonakis
    Division of Infectious Diseases and Department of Molecular Biology, Massachusetts General Hospital, Boston 02114, USA
    Proc Natl Acad Sci U S A 99:15675-80. 2002
    ..neoformans with environmental predators such as free-living nematodes and amoebae and suggest that C. elegans can be used as a simple model host in which C. neoformans pathogenesis can be readily studied...
  76. pmc Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans
    Chiara Luberto
    Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, USA
    J Clin Invest 112:1080-94. 2003
    ..This study identifies App1 as a novel regulator of virulence for C. neoformans, and it highlights that internalization of fungal cells by AMs increases the dissemination of C. neoformans when the host cellular response is impaired...
  77. pmc Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species
    Frank C Odds
    Aberdeen Fungal Group, University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, United Kingdom
    J Clin Microbiol 42:3475-82. 2004
    ....
  78. pmc Gpr1, a putative G-protein-coupled receptor, regulates morphogenesis and hypha formation in the pathogenic fungus Candida albicans
    Takuya Miwa
    Division of Integrated Life Sciences, Graduate School of Biostudies, Kyoto University, Kitashirakawa Oiwake cho, Sakyo ku, Kyoto 606 8502, Japan
    Eukaryot Cell 3:919-31. 2004
    ....
  79. pmc Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection
    Guanggan Hu
    Michael Smith Laboratories, The University of British Columbia, 2185 East Mall, Vancouver, BC, Canada
    Mol Microbiol 69:1456-75. 2008
    ..Taken together, the results reveal specific metabolic adaptations of C. neoformans during pulmonary infection and indicate a role for ACS1 and SNF1 in virulence...
  80. ncbi request reprint Aerosolized antifungal prophylaxis: the winds of change?
    John R Perfect
    Clin Infect Dis 46:1409-11. 2008
  81. ncbi request reprint Recent advances in antifungal pharmacotherapy for invasive fungal infections
    Jason C Gallagher
    Hahnemann University Hospital, Broad and Vine Sts, Mail Stop 451, Philadelphia, PA 19102, USA
    Expert Rev Anti Infect Ther 2:253-68. 2004
    ..Evidence-based studies using these new agents are accumulating, and they are assuming important roles in the pharmacotherapy of invasive fungal infections in seriously ill and complex patients...
  82. ncbi request reprint Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil
    Mariceli A Ribeiro
    Nucleo de Doencas Infecciosas, Centro Biomedico, Universidade Federal do Espirito Santo, Vitoria ES, Brazil
    Med Mycol 43:647-50. 2005
    ..albicans, azole resistance is associated with increased expression of CDR1...
  83. ncbi request reprint Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
    Thomas J Walsh
    Immunocompromised Host Section, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Infect Dis 44:2-12. 2007
    ..Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species...
  84. doi request reprint Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact
    Zeina A Kanafani
    American University of Beirut Medical Center, Beirut, Lebanon
    Clin Infect Dis 46:120-8. 2008
    ....

Research Grants19

  1. Pathobiology of C. neoformans in the Central Nervous System
    John R Perfect; Fiscal Year: 2010
    ....
  2. Pathobiology of C. neoformans in the Central Nervous System
    John R Perfect; Fiscal Year: 2010
    ....
  3. Pathobiology of C. neoformans in the Central Nervous System
    John Perfect; Fiscal Year: 2009
    ....
  4. GENETIC & MOLECULAR BIOLOGY OF VIRULENCE IN C NEOFORMANS
    John Perfect; Fiscal Year: 2003
    ..It is our hypothesis that beginning to understand the genetic regulation of C. neoformans during infection through this proposal will be a powerful tool to find targets to interrupt pathogenesis. ..
  5. GENETIC & MOLECULAR BIOLOGY OF VIRULENCE IN C NEOFORMANS
    John Perfect; Fiscal Year: 2004
    ..It is our hypothesis that beginning to understand the genetic regulation of C. neoformans during infection through this proposal will be a powerful tool to find targets to interrupt pathogenesis. ..
  6. CRYPTOCOCCUS NEOFORMANS--A MODEL FOR PATHOGENIC FUNGI
    John Perfect; Fiscal Year: 2003
    ..This program emphasizes a focus on a single pathogen with a basic but broad-spectrum and highly interactive genomic approach to scientific investigations which can be extrapolated to other fungi. ..
  7. GENETIC & MOLECULAR BIOLOGY OF VIRULENCE IN C NEOFORMANS
    John Perfect; Fiscal Year: 2003
    ..It is our hypothesis that beginning to understand the genetic regulation of C. neoformans during infection through this proposal will be a powerful tool to find targets to interrupt pathogenesis. ..
  8. GENETIC & MOLECULAR BIOLOGY OF VIRULENCE IN C NEOFORMANS
    John Perfect; Fiscal Year: 2002
    ..It is our hypothesis that beginning to understand the genetic regulation of C. neoformans during infection through this proposal will be a powerful tool to find targets to interrupt pathogenesis. ..
  9. GENETIC & MOLECULAR BIOLOGY OF VIRULENCE IN C NEOFORMANS
    John Perfect; Fiscal Year: 2001
    ..It is our hypothesis that beginning to understand the genetic regulation of C. neoformans during infection through this proposal will be a powerful tool to find targets to interrupt pathogenesis. ..
  10. GENETIC & MOLECULAR BIOLOGY OF VIRULENCE IN C NEOFORMANS
    John Perfect; Fiscal Year: 2000
    ..It is our hypothesis that beginning to understand the genetic regulation of C. neoformans during infection through this proposal will be a powerful tool to find targets to interrupt pathogenesis. ..
  11. GENETIC/MOLECULAR BIOLOGY OF VIRULENCE IN C. NEOFORMANS
    John Perfect; Fiscal Year: 1993
    ....
  12. GENTIC & MOLECULAR BIOLOGY OF VIRULENCE IN C. NEOFORMANS
    John Perfect; Fiscal Year: 1992
    ....
  13. GENTIC & MOLECULAR BIOLOGY OF VIRULENCE IN C. NEOFORMANS
    John Perfect; Fiscal Year: 1991
    ....